aInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC;
bDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC;
cDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC;
dLighthouse Trust, Lilongwe, Malawi;
eDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC;
fUNC Project, Lilongwe, Malawi;
gFHI 360, Lilongwe, Malawi;
hRichard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN;
iDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;
jClinical Pharmacology and Analytical Chemistry Core, UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC;
lDivision of Epidemiology, Ohio State University, Columbus, OH; and
kDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Correspondence to: Jane S. Chen, PhD, MSPH, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, 130 Mason Farm Road, Bioinformatics 2nd Floor, Chapel Hill NC 27599 (e-mail: [email protected]).
Supported by National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01 AI083059 to W.C.M.; T32AI007001 to S.E.R.]; and the University of North Carolina Center for AIDS Research (CFAR) [P30 AI050410]. Merck & Co provided raltegravir. Gilead provided emtricitabine/tenofovir. M.S.C. is on the Advisory Board for Merck and Gilead. The remaining authors have no conflicts of interest to disclose.
